Buy Sell or Hold Choose Only One from Top Loser (VRNG, OPNT, BCRX, GTAT)

Los Angelas, CA -- (SBWIRE) -- 11/01/2012 -- Vringo, Inc. (AMEX:VRNG) has been all the rave for months now and during those months it has been a very profitable stock on multiple occasions! On October 3, VRNG traded as low as $3.01 and traded as high as $4.30 - I was able to guide the interested chat users on this trade as we watched it fly on news. Over the next few days, this stock traded to a high of $5.73 and I had mentioned to our chat users that it would be prudent to remove half off the table and set a stop loss. For the rest of the month the stock had declined to a low of $4.28 and then $3.36! Even though it was not the best gain in the world, there was still more opportunities to be exploited on this stock. Trading was halted in VRNG after it announced in court today that it could not collect damages from Google prior to September 15, 2011. The stock then fell sharply and was halted for a few minutes at $2.18.

Is VRNG A Solid Investment At These Levels: Find Out Here

Shares of OPNET (Nasdaq:OPNT) jumped today by as much as 31%, while shares of Riverbed (Nasdaq: RVBD) tanked by as much as 21%, after the latter announced it was acquiring the former. A couple days ago, Riverbed said that it would purchase OPNET for $1 billion in cash and stock, valuing OPNET at $43 per share, hence OPNET's jump today. Riverbed has been in the midst of a broader transition beyond its niche WAN optimization market and into becoming a multi-product company. Adding OPNET will expand Riverbed's network and application performance management offerings. This is a huge bet for Riverbed, as in taking-out-$500-million-in-debt-while-issuing-7-million- new-shares huge. Strategically, the deal makes sense, because Riverbed and OPNET's businesses are indeed complementary and there are synergies to be had. Investors are skeptical today, though, considering the hefty premium that Riverbed is paying for OPNET, as well as the financial risk associated with how the deal is being financed.

How Should Investors React to OPNT Now? Find Out Here

BioCryst Pharmace (Nasdaq:BCRX) reported EPS of -0.985. For the Current Fiscal year, the company is expected to report EPS of -0.71. For the Next Quarter and Next Year, the company is expected to report EPS of -0.12 and -0.18 respectively. At Current Market Price, BCRX is in distance of -31.10% from its 50-day Moving Average price of $4.2236 and -26.58% from its 200-day Moving Average price of $3.9637. BioCryst Pharmaceuticals (NASDAQ:BCRX) withdraws its Investigational New Drug application for the antiviral nucleoside BCX5191, subsequent to talks with the FDA, and shares dive on Wednesday, reaching new 52-week lows. Worries over patient safety were cited by the agency, arising from the pre-clinical toxicity profile of the drug at exposure levels which it believes are likely to be necessary to decrease the viral load in patients which are infected with the hepatitis C virus.

Get The Full Research Report On BCRX For Free: CLICK HERE

GT Advanced (Nasdaq:GTAT) got crushed by as much as 21%, after the company announced a reorganization that entailed massive layoffs. The company is laying off a quarter of its entire workforce, which is expected to reduce annual expenses by $13 million. GT Advanced is consolidating its businesses and looking to reduce costs in the face of a challenging economic environment. The December quarter will see restructuring charges of about $4.2 million as a result. Revenue for the third quarter is expected to come in on the low end of management's guidance of $110 million to $140 million, with complete earnings results to be released on Nov. 6. CEO Tom Gutierrez said that Asian customers are "experiencing severe financial difficulties," and believes that the company's core markets will be challenging next year. However, the company remains optimistic about its long-term prospects in the solar and LED markets.

Can GTAT Continue To Move Higher? Find Out Here

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com